Effective extraction and regeneration of radioactive iodide is one of urgent concerns for the safe utilization of nuclear energy.As a novel environmentally benign ion separation technique,electrochemically switched io...Effective extraction and regeneration of radioactive iodide is one of urgent concerns for the safe utilization of nuclear energy.As a novel environmentally benign ion separation technique,electrochemically switched ion extraction(ESIE)process can be applied for effective capture and recovery of iodide ions(I^(-)).Herein,a novel kelp seaweed-like core/shell I^(-)imprinted polypyrrole@bismuth oxyiodide(PPy/I^(-)@BiOI)composite film is successfully prepared for the selective I^(-)capture in the ESIE system.It is found that the I^(-)can be easily trapped in the PPy/I^(-)@BiOI film after I^(-)is in situ desorbed from the film by an electrochemical reduction process since it offers particular electroactive binding sites for I^(-)extraction.The I^(-)imprinted PPy/I^(-)@BiOI film displays an extraction capacity as high as 325.2 mg·g^(-1)for I^(-)with favorable stability.In particular,the extraction and desorption of I^(-)is achieved by adjusting the redox potential and the pristine PPy/I^(-)@BiOI film can be regenerated and reused for multiple times without decrease in extraction capacity.It is expected that such a PPy/I^(-)@BiOI film would be useful as an electrochemically switched renewable extractor that could capture and regenerate I^(-)from radioactive water.展开更多
Objective:To analyze the efficacy of hyperbaric oxygen at different pressures in the treatment of sudden deafness.Methods:Eighty-two patients with sudden deafness treated in the Affiliated Hospital of Hebei University...Objective:To analyze the efficacy of hyperbaric oxygen at different pressures in the treatment of sudden deafness.Methods:Eighty-two patients with sudden deafness treated in the Affiliated Hospital of Hebei University from September 2019 to September 2021 were selected as the research subjects.The patients were randomly divided into study group 1 and study group 2,and they were treated with hyperbaric oxygen on the basis of routine treatment,in which the pressure used was 1.8 ATA and 2.2 ATA,respectively.Oxygen was delivered via the pressure stabilizing mask for 60 minutes.The patients received two courses of treatment,each lasting 10 days.The changes in hearing(pure tone audiometry)and the clinical efficacy of both the groups were compared before and after treatment.The data obtained were statistically analyzed using SPSS 19.0.Results:The total effective rate of study group 1 was 90.00%,while that of study group 2 was 76.19%.The differences between the two groups were statistically significant(p<0.05).Conclusion:For patients with sudden deafness treated with hyperbaric oxygen,the clinical efficacy of 1.8 ATA is more significant than that of 2.2 ATA.展开更多
Objective:To observe the efficacy and significance of hyperbaric oxygen at different pressures in the treatment of diffuse axonal injury(DAI).Methods:Sixty patients with DAI were randomly divided into 1.8 ATA group(30...Objective:To observe the efficacy and significance of hyperbaric oxygen at different pressures in the treatment of diffuse axonal injury(DAI).Methods:Sixty patients with DAI were randomly divided into 1.8 ATA group(30 cases)and 2.2 ATA group(30 cases).The routine treatment for each group was the same.The 1.8 ATA.group received hyperbaric oxygen therapy under 1.8 ATA on the basis of routine treatment,whereas the 2.2 ATA group received hyperbaric oxygen therapy under 2.2 ATA.on the basis of routine treatment.The therapy was given once a day over 3 consecutive courses,with each course having 10 sessions.The Glasgow Coma Scale(GCS)on day 10,day 20,and day 30 after treatment,as well as the Glasgow Outcome Scale(GOS)after 6 months were compared between the two groups.Results:The mean GCS on day 10,day 20,and day 30 after treatment,as well as the mean GOS after 6 months of treatment in the 2.2 ATA group were significantly higher than those in the 1.8 ATA group(p<0.05).Conclusion:For patients with dififtise axonal injury,hyperbaric oxygen therapy is more effective with 2.2 ATA.compared with 1.8 ATA.展开更多
Lack of effective targeted therapy in metastatic esophageal squamous cell carcinoma(ESCC)underscores the urgent need for identifying new treatment approaches for this challenging disease.We sought to assess the additi...Lack of effective targeted therapy in metastatic esophageal squamous cell carcinoma(ESCC)underscores the urgent need for identifying new treatment approaches for this challenging disease.We sought to assess the addition of cetuximab to paclitaxel-cisplatin chemotherapy for first-line treatment in patients with metastatic ESCC.In this randomized,multicenter,open-label,phase II clinical trial,patients were randomized to receive paclitaxel-cisplatin(TP)(paclitaxel[175 mg/m^(2) intravenously(i.v.)on day 1 of every 3-week cycle]and cisplatin[75 mg/m^(2) i.v.on day 1 of every 3-week cycle])and TP plus cetuximab(CTP)(cetuximab,400 mg/m^(2) i.v.on day 1 of week 1,followed by 250 mg/m^(2) weekly).展开更多
基金Study was supported by the National Natural Science Foundation of China(21871155)the K.C.Wong Magna Fund in Ningbo University,Fan 3315 PlanYongjiang Scholar Plan~~
基金supported by the National Natural Science Foundation of China(U21A20303,22108188,U20A20141)the National Key Research and Development Program of China(2017YFE0129200)+1 种基金the Natural Science Foundation of Shanxi Province(201901D211054)JSPS KAKENHI Grant 19K12395,Japan。
文摘Effective extraction and regeneration of radioactive iodide is one of urgent concerns for the safe utilization of nuclear energy.As a novel environmentally benign ion separation technique,electrochemically switched ion extraction(ESIE)process can be applied for effective capture and recovery of iodide ions(I^(-)).Herein,a novel kelp seaweed-like core/shell I^(-)imprinted polypyrrole@bismuth oxyiodide(PPy/I^(-)@BiOI)composite film is successfully prepared for the selective I^(-)capture in the ESIE system.It is found that the I^(-)can be easily trapped in the PPy/I^(-)@BiOI film after I^(-)is in situ desorbed from the film by an electrochemical reduction process since it offers particular electroactive binding sites for I^(-)extraction.The I^(-)imprinted PPy/I^(-)@BiOI film displays an extraction capacity as high as 325.2 mg·g^(-1)for I^(-)with favorable stability.In particular,the extraction and desorption of I^(-)is achieved by adjusting the redox potential and the pristine PPy/I^(-)@BiOI film can be regenerated and reused for multiple times without decrease in extraction capacity.It is expected that such a PPy/I^(-)@BiOI film would be useful as an electrochemically switched renewable extractor that could capture and regenerate I^(-)from radioactive water.
基金The Youth Scientific Research Fund of the Affiliated Hospital of Hebei University“Observation on the Efficacy of Different Pressure Hyperbaric Oxygen in the Treatment of Sudden Deafness”(Grant Number:2021Q040).
文摘Objective:To analyze the efficacy of hyperbaric oxygen at different pressures in the treatment of sudden deafness.Methods:Eighty-two patients with sudden deafness treated in the Affiliated Hospital of Hebei University from September 2019 to September 2021 were selected as the research subjects.The patients were randomly divided into study group 1 and study group 2,and they were treated with hyperbaric oxygen on the basis of routine treatment,in which the pressure used was 1.8 ATA and 2.2 ATA,respectively.Oxygen was delivered via the pressure stabilizing mask for 60 minutes.The patients received two courses of treatment,each lasting 10 days.The changes in hearing(pure tone audiometry)and the clinical efficacy of both the groups were compared before and after treatment.The data obtained were statistically analyzed using SPSS 19.0.Results:The total effective rate of study group 1 was 90.00%,while that of study group 2 was 76.19%.The differences between the two groups were statistically significant(p<0.05).Conclusion:For patients with sudden deafness treated with hyperbaric oxygen,the clinical efficacy of 1.8 ATA is more significant than that of 2.2 ATA.
文摘Objective:To observe the efficacy and significance of hyperbaric oxygen at different pressures in the treatment of diffuse axonal injury(DAI).Methods:Sixty patients with DAI were randomly divided into 1.8 ATA group(30 cases)and 2.2 ATA group(30 cases).The routine treatment for each group was the same.The 1.8 ATA.group received hyperbaric oxygen therapy under 1.8 ATA on the basis of routine treatment,whereas the 2.2 ATA group received hyperbaric oxygen therapy under 2.2 ATA.on the basis of routine treatment.The therapy was given once a day over 3 consecutive courses,with each course having 10 sessions.The Glasgow Coma Scale(GCS)on day 10,day 20,and day 30 after treatment,as well as the Glasgow Outcome Scale(GOS)after 6 months were compared between the two groups.Results:The mean GCS on day 10,day 20,and day 30 after treatment,as well as the mean GOS after 6 months of treatment in the 2.2 ATA group were significantly higher than those in the 1.8 ATA group(p<0.05).Conclusion:For patients with dififtise axonal injury,hyperbaric oxygen therapy is more effective with 2.2 ATA.compared with 1.8 ATA.
基金This work was supported by the funding from Merck Serono,Co.Ltd.,Beijing,China,an affiliate ofMerck KGaA,Darmstadt,Germany,the Clinical Medicine Plus X-Young Scholars Project of Peking University(PKU2020LCXQ008)the Digestive Medical Coordinated Development Center of Beijing Hospitals Authority(no.XXT19)Beijing Hospitals Authority Youth Programme(QML20191102).
文摘Lack of effective targeted therapy in metastatic esophageal squamous cell carcinoma(ESCC)underscores the urgent need for identifying new treatment approaches for this challenging disease.We sought to assess the addition of cetuximab to paclitaxel-cisplatin chemotherapy for first-line treatment in patients with metastatic ESCC.In this randomized,multicenter,open-label,phase II clinical trial,patients were randomized to receive paclitaxel-cisplatin(TP)(paclitaxel[175 mg/m^(2) intravenously(i.v.)on day 1 of every 3-week cycle]and cisplatin[75 mg/m^(2) i.v.on day 1 of every 3-week cycle])and TP plus cetuximab(CTP)(cetuximab,400 mg/m^(2) i.v.on day 1 of week 1,followed by 250 mg/m^(2) weekly).
